JANX - NASDAQ

Janux Therapeutics, Inc.

JANX·NASDAQ

$13.95

+1.2%

HealthcareBiotechnology

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$850.45M

EPS-1.8300

P/E Ratio-7.62

Earnings Date08/06/2026

janx

Common Stock

Last Annual Value

60.00K

3-Year CAGR

13%

5-Year CAGR

127%

10-Year CAGR

51%

Adjust for Inflation

Janux Therapeutics, Inc. Competitors Analysis of Common Stock

JANX · NASDAQ

Company	Common Stock	CAGR 3Y	CAGR 5Y	CAGR 10Y
Janux Therapeutics, Inc. NASDAQ:JANX	60.00K	9.3%	7.9%	N/A
Biohaven Ltd. NYSE:BHVN	1.93B	29.7%	123.5%	N/A
Nuvation Bio Inc. NYSE:NUVB	1.42B	14.5%	9.3%	N/A
Vera Therapeutics, Inc. NASDAQ:VERA	71.00K	17.3%	27.6%	N/A
Maze Therapeutics, Inc. NASDAQ:MAZE	49.00K	30.6%	N/A	N/A
Celldex Therapeutics, Inc. NASDAQ:CLDX	67.00K	6.2%	7.3%	-5.7%
Harmony Biosciences Holdings, Inc. NASDAQ:HRMY	1.00K	0.0%	0.0%	N/A
Immunome, Inc. NASDAQ:IMNM	11.00K	40.1%	61.5%	N/A
Sionna Therapeutics, Inc. NASDAQ:SION	45.00K	182.3%	N/A	N/A

Janux Therapeutics, Inc. Fair Value Envelope

JANX · NASDAQ

Our analysis suggests that JANX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $13.9454, this represents a potential HIDDEN relative to our calculated worth for Janux Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $13.9454

Related Guides

Blog Categories

Continue your JANX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.